Search

In this paper, we consider an initial and boundary value problem to the three-dimensional (3D) nonhomogeneous nematic liquid crystal flows with density-dependent viscosity and vacuum. Combining delicate energy method with the structure of the system under consideration, the global well-posedness of strong solutions is established, provided that ‖ ρ 0 ‖ L 1 + ‖ ∇ d 0 ‖ L 2 is suitably small. In particular, the initial velocity can be arbitrarily large. Moreover, the exponential decay rates of the strong solution are also obtained. [ABSTRACT FROM AUTHOR]

The exceptional optoelectronic performance and cost‐effectiveness of manufacturing have propelled organic–inorganic hybrid perovskite solar cells (PSCs) into the spotlight within the photovoltaic community. Currently, the single‐junction PSCs have achieved a certified power conversion efficiency surpassing 26%, edging closer to the illustrious Shockley–Queisser theoretical limit. To further enhance device performance, researchers are currently directing their attention toward the integration of wide‐bandgap (WBG) perovskites (Eg > 1.60 eV) as top subcells in conjunction with narrow‐bandgap materials, such as perovskite, crystalline silicon, and copper indium gallium selenium, to construct multijunction tandem devices that maximize solar spectral utilization and minimize thermal losses. However, WBG perovskites encounter challenges associated with suboptimal crystal quality, high defect density, and severe phase separation, leading to significant voltage losses and inferior performance. In this regard, extensive research has been conducted, yielding significant findings. This review article summarizes the advancements in composition engineering, additive engineering, and interface engineering of WBG PSCs. Furthermore, the applications of WBG PSCs in various tandem solar cells and their development are discussed. Finally, future prospects for the development of WBG PSCs are outlined. [ABSTRACT FROM AUTHOR]

We study an initial and boundary value problem to the two dimensional non-isothermal inhomogeneous nematic liquid crystal flow with non-negative density. It is shown that the strong solution exists globally if the gradient of viscosity satisfies $ \|\nabla \mu(\rho)\|_{L^{\infty}(0, T; L^p)} < \infty. $ As an application, we establish the global well-posedness of strong solution to the two-dimensional non-isothermal inhomogeneous nematic liquid crystal flow with constant viscosity for general large initial data. [ABSTRACT FROM AUTHOR]

Introduction: Recent studies suggested the potential benefits of extended infusion times to optimize the treatment efficacy of ceftazidime/avibactam, which indicated that the current pharmacokinetic/pharmacodynamic (PK/PD) target may not be sufficient, especially for severe infections. The purpose of this study is to assess the adequacy of dosing strategies and infusion durations of ceftazidime/avibactam when applying higher PK/PD targets. Methods: This study utilized published PK parameters to conduct Monte Carlo simulations. Different dosages including the recommended regimen based on renal function were simulated and evaluated by the probability of target attainment (PTA) and cumulative fraction of response (CFR). Different PK/PD targets were set for ceftazidime and avibactam. MIC distributions from various sources were used to calculate the CFR. Results: Multiple PK/PD targets have been set in this study, All recommended dosage could easily achieve the target of 50%fT ≥ MIC (ceftazidime) and 50%fT ≥ CT=1.0 mg/L (avibactam). However, for severe infection patients with normal renal function and augmented renal clearance at the recommended dosage (2000 mg/500 mg, every 8 hours), the infusion duration needs to be extended to 3 hours and 4 hours to achieve the targets of 100%fT ≥ MIC and 100%fT ≥ CT=1.0 mg/L. Only continuous infusion at higher dosages achieved 100%fT ≥ 4×MIC and 100%fT ≥ CT=4.0 mg/L targets to all currently recommended regimens. According to the varying MIC distributions, higher concentrations are needed for Pseudomonas aeruginosa, with the attainment rates vary across different regions. Conclusion: The current recommended dosing regimen of ceftazidime/avibactam is insufficient for severe infection patients, and continuous infusion is suggested. [ABSTRACT FROM AUTHOR]